profit from every $100 of sales.
$0$100
TruBridge
We have no price for TruBridge since 13 July 2026. It may have been taken over, merged or renamed, so the figures below are from then.
$26.24+0.00% today
+31.9% since Oct 8, 25
1-year low $14.001-year high $26.25
Trading close to its highest price of the past year.
The essentials
Four questions every investor asks, answered in one line each.
more sales each year, on average, 2022 to 2025.
0%20% a year
You pay $90.39 for every $1 of profit it makes in a year.
CheapExpensive
of earnings would pay off all its debt.
No debt5 years
Money in, money out
What TruBridge sold, what it kept, and what it did with the cash.
Sales went from $327 million in 2022 to $347 million in 2025, with $4.35 million of profit last year.
SalesProfit
TruBridge handed back 10% of the cash it generated last year.
Buybacks $2M
Free cash flow 2025$20M
Bought back its own shares$2M
Paid as dividends–
Cash vs. debt$25M vs. $167M
TruBridge vs. similar companies
TruBridge grows the slowest of these 5 and is the most expensive for its profits.
| Company | Profit from $100 of sales | Sales growth a year | Price per $1 of profit |
|---|---|---|---|
| TruBridge | 90.4× · Very expensive | ||
 GE HealthCare Technologies | 17.9× · Fair price | ||
 Tempus AI | No profit yet | ||
 BrightSpring Health Services | 75.8× · Very expensive | ||
 HealthEquity | 39.6× · Expensive |
AI analysis
An AI analyst reads TruBridge's last five years, its segments, earnings, insiders and peers, and writes the bull case, the bear case and what the price expects.
Run the AI analysisFull statementsIncome, balance sheet and cash flow, year by year
Income statement
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| 327 | 337 | 342 | 347 | |
| 160 | 161 | 173 | 184 | |
| 23 | -7 | 6 | 21 | |
| 48 | -19 | 34 | 42 | |
| 16 | -48 | -21 | 4 | |
| 1.08 | -3.15 | -1.55 | 0.29 | |
| 49.0% | 47.9% | 50.6% | 53.0% | |
| 7.0% | -2.2% | 1.9% | 6.0% | |
| 4.9% | -14.3% | -6.1% | 1.3% |
Balance sheet
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Total assets | 431 | 432 | 396 | 403 |
| Cash | 7 | 4 | 12 | 25 |
| Total debt | 147 | 203 | 175 | 167 |
| Total liabilities | 199 | 248 | 229 | 225 |
| 232 | 184 | 167 | 178 | |
| 14 | 14 | 14 | 14 | |
| 5.1% | -9.2% | 1.3% | 3.7% | |
| 6.8% | -26.2% | -12.5% | 2.4% |
Cash flow
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| 32 | -1 | 31 | 37 | |
| 19 | 22 | 18 | 17 | |
| 13 | -22 | 13 | 20 | |
| Dividends paid | 0 | – | – | – |
| 12 | 3 | 0 | 2 | |
| 5 | 3 | 6 | 9 |
Valuation
- 90.4×
- 10.3×
- –
- 2.1×
- 1.1×
- 19.8×
- 12.6×
- 5.0%
- 1.1%
- 0.0%
Profitability
- 53.0%
- 6.0%
- 1.3%
- 12.3%
- -54.9%
- -1.3%
- 2.5%
- 1.1%
- 6.0%
- 11.5%
Growth
- +2.0%
- −35.5%
- +173.5%
- −34.9%
- +0.3%
Financial health
- 3.1×
- 0.94
- 41.3%
- 3.3×
- 1.78
- 1.77
- 0.85
How it ranks in Healthcare
Each dot is where the company stands among every company over $300M in the sector. Further right is better.
Bottom 5%of 958
Bottom 40%of 888
Bottom 10%of 600
Bottom 21%of 889
Top 23%of 987
What analysts expect
- Average price target
- $25.44
- Range
- $23.00 – $26.25
- 3 analysts
These targets were collected on May 20, 2026 and our analyst feed has not updated since, so we no longer compare them with today's price.
Recent earnings
Our results feed has not updated since May 21, 2026. Results reported after that are not in this table yet.
| Date | EPS | Expected | Surprise |
|---|---|---|---|
| May 8, 2026 | 0.59 | 0.51 | +15.7% |
| Mar 16, 2026 | 0.79 | 0.64 | +24.0% |
| Nov 6, 2025 | 0.88 | 0.40 | +120.0% |
| Aug 7, 2025 | 0.54 | 0.30 | +80.0% |
| May 7, 2025 | 0.36 | 0.29 | +23.6% |
| Mar 10, 2025 | 0.05 | 0.58 | −91.4% |
| Nov 8, 2024 | -0.21 | 0.27 | −177.8% |
| Aug 8, 2024 | 0.16 | 0.19 | −15.8% |
News
No recent news on file.
Insider trades
Our insider feed has not updated since May 26, 2026. Trades filed after that are not listed yet.
No insider trades on file.
The seven classic investing rulebooks
0/7Passes 0 of 7. Each bar is how well the company fits that investor's published rules, from 0 to 100; 60 or more counts as a pass.
Warren Buffett
27No pass
Benjamin Graham
27No pass
Philip Fisher
20No pass
Peter Lynch
16No pass
Joel Greenblatt
1No pass
Charlie Munger
17No pass
Terry Smith
20No pass
Questions about TruBridge
Is TruBridge a good stock to buy?
A business with weak numbers, priced as if everything goes right. 0 of the 7 famous investors' published rulebooks we apply pass it. Whether it suits you depends on your goals and the price you pay; invest-like never tells anyone to buy or sell. The AI analysis lays out the case for and against. Read the TruBridge AI analysis
What does TruBridge do?
TruBridge, Inc. provides healthcare solutions and services for community hospitals, clinics, and other healthcare systems in the United States and internationally. It is in Medical - Healthcare Information Services.
Does TruBridge pay a dividend?
No. TruBridge does not pay a dividend at the moment; in 2025 it returned $1.95 million to shareholders by buying back its own shares.
Is TruBridge stock halal?
No. TruBridge does not pass our halal screen: its debt is 42% of its market value, at or above the 33% limit. How we check
Who are TruBridge's competitors?
The largest listed companies in the same industry are GE HealthCare Technologies, Tempus AI, BrightSpring Health Services and HealthEquity. The peers table on this page compares their profit, growth and price with TruBridge's.
Prices: daily closes to Jul 13, 2026. Fundamentals: company reports via invest-like data.